- Home
- NRIM vs MAZE Comparison
NRIM vs MAZE Comparison
Compare NRIM & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- MAZE
- Stock Information
- Founded
- NRIM 1990
- MAZE 2018
- Country
- NRIM United States
- MAZE United States
- Employees
- NRIM N/A
- MAZE N/A
- Industry
- NRIM Savings Institutions
- MAZE
- Sector
- NRIM Finance
- MAZE
- Exchange
- NRIM Nasdaq
- MAZE NYSE
- Market Cap
- NRIM 500.9M
- MAZE 367.0M
- IPO Year
- NRIM N/A
- MAZE 2025
- Fundamental
- Price
- NRIM $91.60
- MAZE $10.01
- Analyst Decision
- NRIM
- MAZE Strong Buy
- Analyst Count
- NRIM 0
- MAZE 3
- Target Price
- NRIM N/A
- MAZE $25.67
- AVG Volume (30 Days)
- NRIM 55.8K
- MAZE 104.1K
- Earning Date
- NRIM 07-23-2025
- MAZE 05-14-2025
- Dividend Yield
- NRIM 2.81%
- MAZE N/A
- EPS Growth
- NRIM 46.48
- MAZE N/A
- EPS
- NRIM 7.52
- MAZE 0.34
- Revenue
- NRIM $164,695,000.00
- MAZE $167,500,000.00
- Revenue This Year
- NRIM N/A
- MAZE N/A
- Revenue Next Year
- NRIM $7.25
- MAZE N/A
- P/E Ratio
- NRIM $12.18
- MAZE $29.84
- Revenue Growth
- NRIM 26.35
- MAZE N/A
- 52 Week Low
- NRIM $52.10
- MAZE $6.71
- 52 Week High
- NRIM $92.45
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- NRIM 72.56
- MAZE N/A
- Support Level
- NRIM $86.00
- MAZE N/A
- Resistance Level
- NRIM $91.40
- MAZE N/A
- Average True Range (ATR)
- NRIM 2.36
- MAZE 0.00
- MACD
- NRIM 0.02
- MAZE 0.00
- Stochastic Oscillator
- NRIM 89.54
- MAZE 0.00
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.